publication date: Nov. 20, 2015

NCI Announces Winners of its Outstanding Investigator Awards

 

NCI named the inaugural 43 recipients of its Outstanding Investigator Awards.

Developed last year, the grant program provides funding to investigators with outstanding records of productivity in cancer research to support projects of unusual potential in cancer research.

The award provides funding of up to $600,000 in direct costs each year for seven years. One goal of the award is to provide investigators with substantial time to break new ground or extend previous discoveries to advance biomedical, behavioral or clinical cancer research.

Award recipients are cancer researchers, nominated by their institutions, who have served as a principal investigator on an NCI grant for the last five years.

“The NCI Outstanding Investigator Award addresses a problem that many cancer researchers experience: finding a balance between focusing on their science while ensuring that they will have funds to continue their research in the future,” said Dinah Singer, director of NCI’s Division of Cancer Biology.

“With seven years of uninterrupted funding, NCI is providing investigators the opportunity to fully develop exceptional and ambitious cancer research programs.”

The full list of all 43 individual recipients and details of their research are below:

 

Steven Artandi, professor of medicine (hematology) and of biochemistry at Stanford University, for addressing the target cell populations from which cancers emerge and determining how these early beginnings are linked to one of the most fundamental properties of … Continue reading 41-43 NCI Announces Winners of its Outstanding Investigator Awards

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.